Muhammad Shaalan Beg, MD, MBA, explained on Monday how clinical investigators can use new technologies to decentralize clinical trials, conducting portions of the trial at sites distanced from the principal investigator.

Patricia M. LoRusso, DO, PhD (hc), FAACR, focused on one of her greatest passions, oncology drug development, during the Presidential Address on Sunday.

During the session on Sunday, Kathryn C. Arbour, MD, presented promising data on a novel KRAS G12D inhibitor in patients with lung cancer.

John V. Heymach, MD, PhD, reported results on Monday from the first-in-human phase I Beamion LUNG-1 clinical trial of zongertinib in patients with previously treated HER2-mutated NSCLC.

The Monday joint session, chaired by ASCO President Robin Zon, MD, and AACR Immediate Past President Patricia M. LoRusso, DO, PhD (hc), FAACR, addressed opportunities in combining cancer therapy and diagnostic imaging modalities.

During the Monday session, speakers addressed tumorigenic mechanisms driving medulloblastoma and embryonic tumor with multilayered rosettes (ETMR), as well as glioblastoma.

Catherine J. Wu, MD, FAACR, highlighted the promise of personalized neoantigen cancer vaccines—one of four exciting and emerging areas of science examined during the session on Sunday.

Ravindra Uppaluri, MD, PhD, presented results on Sunday that could soon prove practice-changing in patients with head and neck squamous cell carcinoma.

The unity of the cancer research community was on full display Sunday as AACR CEO Margaret Foti, PhD, MD (hc), and thousands of attendees reinforced the life-saving importance of cancer research—no matter the challenges.

During the first Plenary Session on Saturday, Yang Shi, PhD, FAACR, shared his team’s efforts to coax cancer cells toward a less aggressive state through epigenetic mechanisms as a potential treatment approach for patients with acute myeloid leukemia.